Home / Market News / $LQDA

$LQDA news and market catalysts

The 30 most recent market catalysts affecting $LQDA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

30 catalysts 7 high impact 16 bullish 11 bearish Biotechnology
Nov 11, 2026 Corporate Catalyst Bullish Impact 65
Raymond James Maintains Liquidia (LQDA) Buy Rating and Raises Price Target to $77
Raymond James analyst Ryan Deschner has reaffirmed a 'Buy' rating on Liquidia Corporation (LQDA) and raised the price target from $53 to $77. This action signals increased confiden…
Nov 11, 2026 Corporate Catalyst Bullish Impact 55
BTIG Analyst Raises Liquidia Price Target to $87
BTIG analyst Julian Harrison raised Liquidia's price target to $87 from $70, while reaffirming a 'Buy' rating. This adjustment reflects an updated positive outlook on the biopharma…
Nov 11, 2026 Corporate Catalyst Bullish Impact 65
Needham Maintains Buy Rating and Raises Price Target for Liquidia
Needham, a prominent investment firm, has maintained its 'Buy' rating on Liquidia and significantly raised its price target from an unspecified previous level to $66. This action i…
Nov 10, 2026 Corporate Catalyst Neutral Impact 55
Liquidia Corporation Reports Third Quarter 2026 Financial Results
Liquidia Corporation filed an 8-K to announce the release of its third-quarter 2026 financial results and the scheduling of a webcast to discuss these results. This is a standard q…
Oct 15, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
HC Wainwright & Co. analyst Andrew S. Fein has maintained a 'Buy' rating on Liquidia (LQDA) and raised the price target from $58 to $65. This action signals continued bullish senti…
Oct 14, 2026 Corporate Catalyst Bullish Impact 55
Wells Fargo Maintains Equal-Weight on Liquidia, Raises Price Target to $33
Wells Fargo analyst Benjamin Burnett maintained an 'Equal-Weight' rating on Liquidia but raised the price target from $30 to $33. This action signals a modest increase in the analy…
Oct 14, 2026 Corporate Catalyst Bullish Impact 85
Liquidia shares are trading higher after the company announced a global settlement agreement with United Therapeutics, resolving all pending litigation and ensuring YUTREPIA remains available to PAH patients without disruption.
The global settlement agreement between Liquidia and United Therapeutics is a major positive catalyst for Liquidia. The resolution of all pending litigation removes a significant s…
Oct 14, 2026 Corporate Catalyst Bullish Impact 95
Liquidia Settles Bitter Fight With United Therapeutics
Liquidia (LQDA) has reached a comprehensive settlement with United Therapeutics (UTHR) for $380.7 million, ending years of bitter legal battles. This resolution is a major positive…
Oct 14, 2026 Corporate Catalyst Bearish Impact 65
Needham Maintains Buy on Liquidia, Lowers Price Target to $58
Needham analyst Serge Belanger maintained a 'Buy' rating on Liquidia but significantly lowered the price target from $72 to $58. This action indicates that while the analyst still …
Oct 14, 2026 Corporate Catalyst Bullish Impact 65
BTIG Upgrades Liquidia to Buy, Announces $70 Price Target
BTIG analyst Julian Harrison upgraded Liquidia (LQDA) from Neutral to Buy and announced a $70 price target. This upgrade reflects a more optimistic outlook from a prominent investm…
Oct 14, 2026 Corporate Catalyst Bullish Impact 95
Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know
Liquidia Corporation has reached a global settlement with United Therapeutics, ending all ongoing patent litigation. This resolution follows a court ruling that found Liquidia infr…
Oct 13, 2026 Corporate Catalyst Neutral Impact 75
Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD
Liquidia has settled a patent infringement lawsuit concerning its YUTREPIA product's use for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company …
Oct 2, 2026 Corporate Catalyst Bearish Impact 75
Wells Fargo Downgrades Liquidia to Equal-Weight, Lowers Price Target to $30
Wells Fargo analyst Benjamin Burnett downgraded Liquidia (LQDA) from 'Overweight' to 'Equal-Weight' and drastically cut the price target from $108 to $30. This move signals a signi…
Oct 1, 2026 Corporate Catalyst Bearish Impact 75
Raymond James Downgrades Liquidia to Outperform, Lowers Price Target to $53
Raymond James analyst Ryan Deschner downgraded Liquidia's rating from 'Strong Buy' to 'Outperform' and slashed the price target from $106 to $53. This significant revision suggests…
Oct 1, 2026 Corporate Catalyst Bearish Impact 75
Liquidia shares are trading lower after BTIG downgraded its rating on the stock from Buy to Neutral. Also, Needham maintained its Buy rating and lowered its price target from $110 to $72.
This headline presents a mixed but predominantly negative signal for Liquidia. The BTIG downgrade from Buy to Neutral is a direct negative catalyst, indicating a loss of confidence…
Oct 1, 2026 Corporate Catalyst Bearish Impact 85
Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute
A U.S. District Court ruled that Liquidia infringed on two claims of United Therapeutics' patent related to Yutrepia for PH-ILD. This is a significant blow to Liquidia as it could …
Oct 1, 2026 Corporate Catalyst Bearish Impact 55
BTIG Downgrades Liquidia to Neutral
BTIG analyst Julian Harrison downgraded Liquidia (LQDA) from a 'Buy' to a 'Neutral' rating. This is a direct change in a financial institution's recommendation for the company's st…
Oct 1, 2026 Corporate Catalyst Bearish Impact 65
Needham Maintains Buy on Liquidia, Lowers Price Target to $72
Needham analyst Serge Belanger has revised the price target for Liquidia (LQDA) from $110 to $72, while reiterating a 'Buy' rating. This significant reduction in the price target, …
Oct 1, 2026 Corporate Catalyst Bearish Impact 95
Why is Liquidia (LQDA) Stock Trending After Hours?
The core event is a federal court ruling in favor of United Therapeutics (UTHR) regarding two patent claims against Liquidia's (LQDA) lead product, Yutrepia. This is highly signifi…
Sep 30, 2026 Corporate Catalyst Bearish Impact 95
Liquidia shares are trading lower after a Delaware court ruled that two key United Therapeutics patent claims covering PH-ILD treatment with inhaled treprostinil are valid and infringed by the company's lead product, YUTREPIA, despite other asserted patent claims being invalidated.
This court ruling is a critical corporate catalyst for both Liquidia and United Therapeutics. For Liquidia, the finding of infringement on key patents for their lead product, YUTRE…
Sep 3, 2026 Corporate Catalyst Neutral Impact 65
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
The filing highlights Caligan Partners' investment strategy in the volatile biotech sector, emphasizing their 'private equity owner' approach with concentrated positions and active…
Sep 3, 2026 Corporate Catalyst Bullish Impact 75
FDA Fast-Tracks Liquidia Drug for Painful Systemic Sclerosis Complication
The FDA's Fast Track designation for Liquidia's YUTREPIA is a significant positive catalyst for the company. This designation is granted to therapies that address serious condition…
Sep 3, 2026 Corporate Catalyst Bullish Impact 75
Liquidia Receives FDA's Fast Track Designation For YUTREPIA Inhalation Powder To Treat Raynaud's Phenomenon Associated With Systemic Sclerosis
Liquidia Corporation announced that the FDA granted Fast Track designation to YUTREPIA for Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). This is a significant p…
Aug 13, 2026 Corporate Catalyst Bullish Impact 65
Wells Fargo Maintains Overweight on Liquidia, Raises Price Target to $108
Wells Fargo analyst Benjamin Burnett has maintained an 'Overweight' rating on Liquidia and raised the price target from $62 to $108. This substantial increase in the price target, …
Aug 13, 2026 Corporate Catalyst Bullish Impact 55
B of A Securities Maintains Neutral on Liquidia, Raises Price Target to $92
B of A Securities analyst Jason Gerberry updated his coverage on Liquidia, raising the price target from $79 to $92 while keeping a 'Neutral' rating. This adjustment reflects a rev…
Aug 12, 2026 Corporate Catalyst Bearish Impact 65
LifeSci Capital Downgrades Liquidia to Market Perform, Announces $90 Price Target
LifeSci Capital analyst Gaurav Maini downgraded Liquidia (LQDA) from 'Outperform' to 'Market Perform' and announced a $90 price target. This downgrade signals a potentially less op…
Aug 12, 2026 Corporate Catalyst Bullish Impact 65
Needham Maintains Buy on Liquidia, Raises Price Target to $110
Needham analyst Serge Belanger maintained a 'Buy' rating on Liquidia and raised the price target from $70 to $110. This substantial increase in the price target signals a strong po…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Liquidia, Raises Price Target to $111
BTIG analyst Julian Harrison has updated their coverage on Liquidia, raising the price target by $2 to $111 while maintaining a 'Buy' rating. This action signals continued bullish …
Aug 12, 2026 Market Technicals Bearish Impact 75
Liquidia shares are trading lower despite reporting better-than-expected Q2 financial results. The stock may be experiencing some profit taking after rising approximately 200% since the end of March.
This headline primarily reflects market technicals, specifically profit-taking, rather than a fundamental shift in the company's outlook. The significant 200% rise since March like…
Aug 12, 2026 Corporate Catalyst Bullish Impact 95
Liquidia Q2 EPS $0.74 Beats $0.41 Estimate, Sales $171.679M Beat $116.675M Estimate
Liquidia reported exceptional Q2 results, with EPS beating estimates by over 80% and sales exceeding expectations by more than 47%. This represents a massive turnaround from a loss…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.